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Abstract
Background: Since early 2020, the Covid-19 pandemic has engulfed the world. Amidst the growing number of
infections and deaths, there has been an emphasis of patients with non-communicable diseases as they are
particularly susceptible to the virus. The objective of this literature review is to systematize the available evidence
on the link between non-communicable diseases and Covid-19.
Methods: We have conducted a systematic review of the literature on Covid-19 and non-communicable diseases
from December, 2019 until 15th of November, 2020. The search was done in PubMed and in doing so we used a
variety of searching terms in order to isolate the final set of papers. At the end of the selection process, 45 papers
were selected for inclusion in the literature review.
Results: The results from the review indicate that patients with certain chronic illnesses such as diabetes,
hypertension (and other cardiovascular diseases), chronic respiratory illnesses, chronic kidney and liver
conditions are more likely to be affected by Covid-19. More importantly, once they do get infected by the
virus, patients with chronic illnesses have a much higher likelihood of having worse clinical outcomes
(developing a more severe form of the disease or dying) than an average patient. There are two
hypothesized channels that explain this strong link between the chronic illnesses enumerated above and
Covid 19: (i) increased ACE2 (angiotensin-converting enzyme 2) receptor expressions, which facilitates the
entry of the virus into the host body; and (ii) hyperinflammatory response, referred to as “cytokine storm”.
Finally, the literature review does not find any evidence that diabetes or hypertension related medications
exacerbate the overall Covid-19 condition in chronic illness patients.
Conclusions: Thus, the evidence points out to ‘business as usual’ disease management model, although with
greater supervision. However, given the ongoing Covid-19 vulnerabilities among people with NCDs,
prioritizing them for the vaccination process should also figure high on the agenda on health authorities.
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Introduction
The novel Respiratory Syndrome Coronavirus-2 (SARS-
CoV-2) caused a cluster of pneumonia cases in China at
the end of 2019. After a few months, it led to a pan-
demic that has spread throughout most countries of the
world. SARS-CoV-2 disease (Covid-19) primarily mani-
fests as a lung infection and its clinical course is charac-
terized by respiratory symptoms ranging from a mild
respiratory infection (including fever, cough and fatigue)
to pneumonia, acute respiratory distress syndrome
(ARDS), shock, and death. While Covid-19 had been ini-
tially considered as a respiratory infection, causing harm
primarily through inflammatory and immunological pro-
cesses in the respiratory tract, emerging evidence points
out that patients with non-communicable diseases
(NCDs) are at higher risk of contracting Covid-19 and
suffering worse consequences; moreover, emerging evi-
dence points to a strong feedback mechanism between
Covid-19 and existing chronic illnesses (e.g. diabetes)
thus further contributing to organ damage and fatal
consequences.
The interplay between Covid-19 and NCD shows a set
of different effects, both direct and indirect. Direct ef-
fects relate primarily to the fact that there is a significant
number of preliminary reports connecting certain pre-
existing conditions, such as cardiac failure, coronary
heart disease, hypertension and diabetes, to a more se-
vere course of Covid-19. Thus, comorbidities may play
an important role both in increased susceptibility for in-
fection with SARS-CoV-2 as well as increase the risk of
a more severe course of the disease. For now, it seems
that an important mechanism is inflammation in the
small vessels, particularly in the heart and lungs, but po-
tentially also in other organs, e.g. digestive tract.
Indirect effects are more difficult to measure as they
may range from the avoidance of using health services
due to the fear of infection. This may lead to: (a) delays
in the diagnosis of more acute conditions, such as acute
myocardial infarction (AMI) or stroke (CVI); (b) skip-
ping screening appointments or their cancellation due to
the running epidemic; (c) lengthening of the waiting lists
for diagnostic and therapeutic procedures.
An important feature of the Covid-19 pandemic is also
the fact that the knowledge about it is only being gained
and it is still unfolding. We are faced with an interesting
challenge, where it has become easy to publish quickly
about the different findings. But this goes against the sci-
entific rigor in some cases. It is essential to exert an
above average level of caution when interpreting results.
Against this background, we conduct this literature re-
view with the main purpose of shedding more light on:
(i) the prevalence of Covid-19 (and hence susceptibility)
among patients with chronic illnesses; (ii) the analytical
link between NCDs, disease progression and disease
outcome among patients with selected NCDs; (iii) the
pathways through which Covid-19 impacts upon pa-
tients with various NCDs from a clinical perspective and
(iv) to provide a more definitive answer on the link be-
tween medications used to manage various NCDs and
Covid-19 progression and outcome.
Methodology
We conducted literature review on published papers
from 31st of December, 2019 until the 15th of Novem-
ber, 2020. The search was done in PubMed and in doing
so we used a variety of searching terms in order to iso-
late the final set of papers. The template below provides
a snapshot of the search mechanisms that we used:
(“covid 19” or “COVID 19” or “sars Cov 2” or “corona-
virus” or “corona virus”) and (“non communicable dis-
eases” or “non communicable disease” or “NCD” or
“NCDs” or “chronic illnesses” or “chronic diseases”)
As well as
(“covid 19” or “COVID 19” or “sars Cov 2” or “corona-
virus” or “corona virus”) and (“diabetes” or “cardiovascu-
lar diseases” or “hypertension” or “cancer” or “kidney
disease”).
The studies that were extracted were carefully exam-
ined. The inclusion criteria included, inter alia, preva-
lence of the NCDs in the search criteria. Moreover, we
also included studies that reported clinical outcomes in
form of disease severity as well as death. The studies
were limited to adult humans and had to be written in
English in order to be considered. Duplicate studies, let-
ters, case reports, abstracts, studies written in languages
other than English were excluded.
No ethical approval was needed, given that this was a
literature review of published studies.
Figure 1 above provides a snapshot of the selection cri-
teria for the papers in this literature review. Initially,
2732 records were identified and after screening for ti-
tles, abstracts and full papers, 45 records were retained
which were used in this literature review and which we
elaborate on throughout this paper.
Results
Covid-19 and diabetes
Most of the studies included in this literature review
study the link between Covid-19 and diabetes (Table 1).
A strand of this literature has focused on studying the
prevalence of diabetes in Covid-19 patients, albeit de-
scriptively. According to the existing studies, the preva-
lence of diabetes in Covid-19 patients varies, but it is
almost always in double digit levels. More specifically,
the prevalence of diabetes among Covid-19 patients
ranges from 14% [1], 17% [2], 22% [3] to 44% [4] (Add-
itional file 1: Table A1).
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A special strand of the literature has also focused on a
more analytical link between diabetes and Covid-19, fo-
cusing on a few specific outcomes, such as mortality or
severity of the disease. The common thread in this
strand of the literature is that patients with diabetes
show a consistently lower likelihood of survival or recov-
ery and are much more likely to have a severe disease
progression, compared to the non-diabetic patients.
In a retrospective case series, Yan et al. [5] for ex-
ample, report that the survival rate was lower among the
diabetic patients compared to the non-diabetic ones.
More specifically, in their study, the HR was 1.5 (95% CI
1.0–2.3) after adjustment for demographic factors. Simi-
larly, Yan et [6] find the patients with diabetes had con-
sistently and independently poorer outcomes with a
relative risk of dying at 3.0 (95% CI 1.3–6.8). In the con-
text of Mexico, a study also found that diabetes is associ-
ated with hospitalization and worse outcomes among
patients with Covid-19. These findings are echoed in
some existing literature reviews [7]. For example, in a
study by Du et al. [8], the risk of severe cases was higher
in Covid-19 patients with diabetes (RR = 2.1, 95%CI 1.8–
2.6) and the risk of death was also higher in Covid-19
patients with diabetes (RR = 3.2, 95%CI 2.6–3.8). Fur-
thermore, and going beyond mortality as an outcome,
Praveen et al. [9] find that diabetes was lower in the sur-
vivors (OR: 0.6; 95%CI: 0.4–0.9) and non-severe patients
(OR: 1.7; 95%CI 1.2–2.3). Finally, Noor et al. [10] found
a significant association between Covid-19 and mortality
among diabetes patients (RR 1.9, 95% CI 1.2–2.8).
A few of the literature reviews that we include have con-
ducted meta-analyses in order to further unearth the link
between diabetes and Covid-19 mortality. In most of the
cases, the authors find statistically significant link between
diabetes and dying from Covid-19 with odds ratios higher
than one. In a meta-analysis by Wu et al. [11], the authors
find a close link between diabetes and mortality with OR
of 1.75. In another literature review conducted by Ssento-
noga et al. [12], diabetes was associated with a significantly
greater risk of mortality from Covid-19 (OR 1.5, 95% CI
1.0–2.2). In the rest of the studies, the odds ratios captur-
ing the link between diabetes and Covid-19 mortality tee-
ter around 2.5 [13–17]. In only one of the studies the odds
ratios of death due to Covid-19 among diabetics were
higher than 3. More specifically, Lu et al. [18] find that
diabetes comorbidity was one of the key mortality risk fac-
tors (OR = 3.7, 95% CI 2.4–5.9). Furthermore, and taking a
more comprehensive approach Awortwe et al. [19] suggest
that cardio-metabolic syndrome (mainly characterized by
insulin resistance, impaired glucose tolerance, dyslipid-
emia, hypertension, and central adiposity) is associated
with negative clinical outcomes including mortality (risk
difference RD 0.1, 95%-CI 0.1–0.2), admission to ICU (RD
0.1, 95%-CI 0.04–0.2) and severe infection (RD 0.1, 95%-
CI 0.01–0.09) in Covid-19 patients (Additional file 1:
Table A1).
Fig. 1 Flow chart of the publication selection process. Source: Authors
Nikoloski et al. BMC Public Health         (2021) 21:1068 Page 3 of 9
Covid-19 and hypertension/cardiovascular diseases
The second most studied set of chronic illnesses are car-
diovascular illnesses, including hypertension (Table 1).
Similarly, to the case of diabetes, one strand of the litera-
ture has focused descriptively on the prevalence of
hypertension and cardiovascular diseases among Covid-
19 patients. In a literature review, Wolff et al. [20], es-
tablish that, along with diabetes, hypertension and other
cardiovascular diseases are the most prevalent chronic
illnesses among Covid-19 patients. The prevalence of
hypertension in Covid-19 patients vary, from 15.6% [4],
16.4% [21], 22% [1], 27.4% [2] to 38.6% [3]. Similarly, the
prevalence of other cardiovascular diseases is in double-
digits varying form 4.7% [4], 8.9% [2], 12.1% [21], 13%
[1] to 17.5% [3]. (Additional file 1: Table A2).
In the second strand of the literature, the authors es-
tablish a more analytical link between hypertension (and
the rest of the cardiovascular diseases) and negative clin-
ical outcomes (e.g. death or severity of illness) among
Covid-19 patients. In that respect, the link between
hypertension and Covid-19 outcomes is particularly
studied. A very comprehensive literature review by Pra-
nata et al. [22] suggests that hypertension was associated
with increased composite poor outcome (risk ratio (RR)
2.1 95% CI 1.9–2.4) and its sub-group, including mortal-
ity (RR 2.2 95% CI 1.7–2.8), severe Covid-19 (RR 2.0, CI
1.7–2.5), ARDS (RR 1.6, 95% CI: 1.1–2.4), ICU care (RR
2.1, 95% CI: 1.3–3.3), and disease progression (RR 3.0,
95% CI: 1.5–6.0). Similarly, in a literature review by
Parveen et al. [9], hypertension was positively associated
with death (OR: 0.5; 95% CI: 0.3–0.7), ICU care (OR:
0.4; 95%CI: 0.2–0.8) and severity (OR: 2.7; 95% CI 1.3–
5.7) (Additional file 1: Table A2).
While establishing a link between hypertension and
Covid-19 mortality, most of the literature reviews also
conduct meta-analyses, which find significantly higher
odds of Covid-19 mortality among hypertensive patients,
with odds ratios usually ranging from 2.5 to 3 [10, 12–
14, 23–25]. Finally, only in one of the meta-analyses
were the odds ratios of dying from Covid-19 among
hypertensive patients was higher than 3. More specific-
ally, a literature review by Liu et al. [17] confirms the
Table 1 Type of studies included in the literature review
Chronic illness Number of studies Share of total studies included in the review Type of studies included, (N)
Diabetes 33 73 Retrospective, observational study (2)




Multi-centre cross sectional study (1)
National reporting data analysis (1)
Hypertension/cardiovascular disease 28 62 Nested case-control design (1)
Literature review (22)
Observational study (1)
Retrospective case series analysis (2)
Multi-centre cross sectional study (1)
National reporting data analysis (1)
COPD/other respiratory illnesses 11 24 retrospective cohort study (1)
clinical analysis of electronic records (1)
literature review (8)
Retrospective case series analysis (1)
Chronic kidney disease 9 20 Retrospective case series analysis (1)
literature review (8)
Cancer 10 22 retrospective cohort study (2)
Literature review (7)
Multi-centre cross sectional study (1)
Chronic liver disease 4 9 Literature review (4)
Asthma 7 16 demographic analysis (1)
Study of medical records (1)
Literature review (5)
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finding that hypertension (OR 3.4, 95% CI 2.5–4.7) was
one of the key mortality risk factors.
Similarly, to hypertension, a strand of this literature
has focused exclusively on the clinical outcomes of
Covid-19 patients with other cardio-vascular comorbidi-
ties. In a study by Gu et al. [26], the estimated mortality
risk in patients with pre-existing coronary heart disease
(CHD) was three times that of those without CHD. The
estimated 30-day survival probability for a profile patient
with pre-existing CHD (65-year-old woman with no
other comorbidities) was 0.5 (95% CI 0.3–0.8). Further-
more, a study in Oman [27] found that patients with
cardiac injury had higher mortality than those without
cardiac injury (53.3% vs 7.1%). The literature review by
de Almeida-Pittito [13] mentioned above also suggested
that cardiovascular disease was strongly associated with
both severity and mortality, respectively (OR 4.0 95% CI
2.8–5.9 and OR 6.3 95% CI 3.7–10.8) also reflecting the
previous findings [10]. In addition, the literature review
by Matshushita et al. [23] suggested that acute myocar-
dial injury, determined by elevated high-sensitivity
troponin levels, is commonly observed in severe cases,
and is strongly associated with mortality. Moreover, a
comprehensive review by Ssentonoga et al. [12] found
that cardiovascular disease (risk ratio (RR) 2.3, 95% CI
1.6–3.2) and congestive heart failure (RR 2.03 95% CI
1.3–3.2) were associated with a significantly greater risk
of mortality from Covid-19. A review by Khan et al. [16]
found that higher likelihood of dying was found among
Covid-19 patients who had pre-existing cardiovascular
diseases (odds ratio 3.4 95% CI 2.9–4.1), reflecting the
findings by Liu et al. [17]. Finally, a literature review by
Hessami et al. [28] indicated that acute cardiac injury,
(OR: 13.3, 95% CI 7.4–24.0), heart failure (OR: 6.7, 95%
CI 3.3–13.5), arrhythmia (OR: 2.8, 95% CI 1.4–5.3), cor-
onary artery disease (OR: 3.8, 95% CI 2.4–5.9), and car-
diovascular disease (OR: 2.6, 95% CI 1.9–3.6) were
significantly associated with Covid-19 mortality (Add-
itional file 1: Table A2).
Covid-19 and COPD
The third most prevalent chronic illness associated with
negative outcomes due to Covid-19 is COPD (chronic
obstructive pulmonary disease) as well as other under-
lying chronic illnesses. As in the rest of the literature,
here as well, there are two strands that emerge: one of
them is focused on the link between Covid-19 and
chronic respiratory illnesses from a descriptive point of
view, while the second strand is more analytical. In their
literature review, Mahmud et al. [1] and Bajgain et al. [2]
find that most prevalent chronic comorbid conditions
were, inter alia, respiratory diseases (5%).
The second strand of the literature is more analytical
and tries to establish a more robust link between pre-
existing chronic lung illnesses and Covid-19 disease out-
comes. Nachtigall et al. [29] for example argue that pre-
existing lung disease was one of the main predictors of
death (HR 1.6; 95%CI 1.2–2.2). Similarly, Lu et al. [18]
in a literature review suggest that chronic lung disease
(OR 3.4, 95% CI 1.8–6.5) was one of the key mortality
risk factors, which is further echoed in the other studies
included in this literature review [14, 16, 17] (Additional
file 1: Table A3).
Finally, a special strand of the literature has focused
on COPD as the most dominant pulmonary chronic ill-
ness and its link with Covid-19. Graziani et al. [30] find
that compared with COPD-free individuals, COPD pa-
tients with Covid-19 showed significantly poorer disease
prognosis, as evaluated by hospitalizations (31.1% vs.
39.8%: OR 1.6; 95% CI 1.1–1.2) and mortality (3.4% vs.
9.3%: OR 2.9; 95% CI 2.3–3.8). In their literature review,
Awortwe et al. [19], indicated that chronic obstructive
pulmonary disease, inter alia, worsen the clinical out-
comes including mortality (risk difference RD 0.1, 95%-
CI 0.05–0.2), admission to ICU (RD 0.1, 95%-CI 0.04–
0.2) and severe infection (RD 0.05, 95%-CI 0.01–0.09) in
Covid-19 patients (Additional file 1: Table A3).
Covid-19 and chronic kidney disease
The fourth most common chronic illnesses associated
with negative outcomes related to Covid-19 are chronic
kidney diseases. In a literature review by Bajgain et al.
[2], around 2.6% of patients with chronic kidney disease
also had Covid-19.
A literature review by Awowrtwe et al. [19] found a sig-
nificantly higher likelihood of poor Covid-19 outcomes
among patients with chronic kidney disease. Results sug-
gested that chronic kidney disease, inter alia, was associ-
ated with worse clinical outcomes including mortality
(risk difference RD 0.1, 95%-CI 0.1–0.12), admission to
ICU (RD 0.1, 95%-CI 0.04–0.2) and severe infection (RD
0.05, 95%-CI 0.01–0.09) in Covid-19 patients. A literature
review by Sepandi et al. [14] found that some chronic dis-
eases such as kidney disorder (OR 2.6 95% CI 1.2–5.6) can
increase the risk of Covid-19 mortality, which is similar to
the rest of the studied included in this review [12, 16, 31]
(Additional file 1: Table A4).
Covid-19 and cancer
As in the rest of the chronic illnesses the literature on
the link between Covid-19 and cancers could be divided
into two strands. In the first one, authors are mainly
concerned with finding the prevalence of cancer among
Covid-19 patients. The literature reviews that we cover
suggest prevalence of cancer among Covid-19 patients
ranging from 1.2% [4] to 3.5% [2] and 8% [1] (Table A5).
The second strand of the literature has analytically
established a link between cancer and Covid-19
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outcomes. In a literature review by Noor et al. [10] a sig-
nificant association were found between mortality
among Covid-19 infected patients and cancer (RR 2.3,
95% CI 1.8–3.0). Similarly, a literature review by Ssento-
noga et al. [12] found that cancer (1.5 95% CI 1.01 to
2.2) was associated with a significantly greater risk of
mortality from Covid-19. In their own review, Khan
et al. [16] suggest higher likelihood of deaths was found
among Covid-19 patients who had any types of cancers
(OR 2.2, 95% CI 1.6–3.0). Finally, and specifically focus-
ing on cancer patients, Zhang et al. [32] find a signifi-
cantly higher mortality rate, particularly if the anti-
tumour treatment was within the last 14 days. There is a
nuance however. While existing evidence finds that the
fatality rate in the lung cancer patients with Covid-19
was 32.9% (95% CI 27.9 to 38.0%) and the fatality rate in
haematological cancer patients was 34.2% (95% CI 23.1
to 46.2%), in other types of solid cancer excluding lung,
the overall case fatality and severe event rates were
17.2% (95% CI 12.3 to 22.7%) [33]. Similarly, another
study finds that patients with solid versus hematologic
cancers exhibit different clinical outcomes, with patients
with hematologic cancers having a significantly higher
mortality relative to patients with solid cancers after ac-
counting for confounders [34].
Covid-19 and liver disease
The literature on the link between Covid-19 and chronic
liver disease is less sanguine. In three of the four studies
that we had identified, there is a clear link between exist-
ing liver chronic illness and higher likelihood of mortal-
ity. Oyelade et al. [35] found that in patients with Covid-
19 and underlying liver diseases, 57.3% (43/75) of cases
were severe, with 17.65% mortality. Khan et al. [16]
found that there was a higher likelihood of deaths was
found among Covid-19 patients who had pre-existing
liver diseases (OR = 2.4, 95% CI 1.5–3.7), echoing previ-
ously established notion [10]. However, in another litera-
ture review, Wang et al. [31] found no relationship
between Covid-19 mortality and pre-existing liver dis-
ease (Table A6).
Covid-19 and asthma
As in the rest of the cases, a strand of the literature has
focused on estimating the prevalence of asthma among
Covid-19 patients. In a study in South Korea, the preva-
lence of asthma among Covid-19 patients was 2.9% [36],
somewhat similar to another review which finds that
asthma is a pre-morbid condition in about 1.6% of the
Covid-19 patients [37]. Another systematic review of the
link between asthma and Covid-19 finds a somewhat
higher prevalence of asthma among Covid-19 patients
(7.46%) [38] echoing the heterogeneity of prevalence
across different countries and regions as reported in an-
other systematic review [39].
The second strand of the literature has focused on
studying the clinical outcomes of asthma patients with
Covid-19. A systematic literature review finds that there
was no significant difference in the combined risk of re-
quiring admission to ICU and/or receiving mechanical
ventilation for people with asthma (RR 0.87, 95% CI
0.94–1.37) and risk of death from Covid-19 (RR 0.87;
95% CI 0.68–1.10) [38].These findings are similar to the
ones conducted in another meta-analysis [40, 41]. Over-
all, the literature suggests that asthma is not an inde-
pendent risk factors for the clinical outcomes of Covid-
19 [36]. In a study by Chibba et al. [42], asthma was not
associated with an increased risk of hospitalization (rela-
tive risk, 0.96; 95% CI, 0.8–1.2) after adjusting for age,
sex, and comorbidities. Similarly, a literature review by
Morais-Almeida et al. [43] found that there is no strong
evidence supporting that patients with asthma have a
higher risk of becoming seriously ill from coronavirus
disease 2019 (Table A7).
Discussion
There are a few findings that stem from this review on
the link between Covid-19 and non-communicable dis-
eases. First, as evidenced by this review, studies have ob-
served a high prevalence of certain chronic illnesses
(diabetes, hypertension) among Covid-19 patients. Sec-
ond, and going beyond descriptive observation, majority
of the studies find that Covid-19 patients have higher
likelihood of worse clinical outcomes (e.g. higher mortal-
ity) compared to patients without chronic illnesses. This
is particularly the case for diabetes, hypertension, COPD
and chronic kidney disease. Third, while our findings are
similar for the rest of the chronic illnesses featured in
this review, they are less sanguine in the case of chronic
liver disease. Finally, the result of the literature review
suggests no link between asthma and Covid-19.
While the research on the interplay between diabetes
and Covid-19 is still ongoing, there are a few preliminary
findings/research hypotheses that have been put forth as
to why diabetic patients are associated with more pro-
nounced Covid-19 complications.
First, the existing knowledge suggests that patients
with chronic illnesses (diabetes, hypertension, other
cardio-vascular diseases, chronic kidney disease) have in-
creased ACE2 (angiotensin-converting enzyme 2) recep-
tor expressions, which facilitates the entry of the virus
into the host body [44]. Moreover, as the study by Ere-
ner et al. [45] suggests, ACE2 is expressed in various tis-
sues including the lung, heart, kidney tubules, the
luminal surface of the small intestine, blood vessels,
endocrine and exocrine pancreas [45]. Similar explana-
tions, specific to cardio-vascular diseases have been put
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forth by Pranata et al. [22]. In the case of asthma, it has
been argued that respiratory epithelial cells in patients
with asthma have decreased gene expression for ACE2
receptors and therefore may be protective against Covid-
19 infection [46].
Another potential reason for the increased risk of se-
vere Covid-19 disease in patients with chronic illnesses
might be attributed to the hyperinflammatory response,
referred to as “cytokine storm” [47, 44]. Patients with
certain chronic illnesses (e.g. diabetes, hypertension) suf-
fer from a continuous low-grade inflammation facilitat-
ing the emergence of a cytokine storm, which in turn
appears to be directly related to the severity of Covid-19
pneumonia cases and to subsequent death [47]. More
specifically, patients with diabetes appear to have an im-
paired adaptive immune response characterized by an
initial delay of Th1 cell-mediated immunity and a late
hyperinflammatory response. In the absence of an
immunostimulant, diabetes is associated with an in-
creased pro-inflammatory cytokine response marked by
increased secretion of IL-1, IL-6, IL-8 and TNF-α, which
in turn play a more deleterious role in Covid-19 infec-
tion [44, 45]. When specifically focusing on cancer,
ACE2 and TMPRSS2 expression is found higher in can-
cer patients, and coagulopathy is a potential risk ob-
served in a number of cancer patients [48]. Different
hypotheses have been put forth regarding the differences
in clinical outcomes between Covid-19 patients with
solid vs. hematologic cancers. A study has found that the
principal cause of elevated mortality risk from Covid-19
in solid cancer patients is cancer progression [49]. In
contrast, the same study suggests that in haematological
cancer patients, there was a particularly striking expres-
sion of exhaustion markers by CD8+ T cells. Exhausted
T cells, in turn, may compromise virus clearance [49].
These links between Covid-19 and some of the chronic
illnesses mentioned above have implications on the impact
of current medical treatments for certain chronic illnesses
on the probability of developing severe Covid-19. How-
ever, the results presented in studies covered in this litera-
ture review reveal that there is no evidence to support this
hypothesis currently. In view of lack of robust evidence for
either benefit or harm, it is reasonable for patients to con-
tinue using ACE inhibitors and ARB, as recommended by
European Society of Cardiology Council on Hypertension,
European Society of Hypertension and American Heart
Association [44]. Moreover, there are several studies about
the protective effect of statins in pneumonia [44]. Statins
are known to increase ACE-2 levels and may protect
against viral entry of SARS CoV-2. However, this increase
in ACE-2 could be counterintuitive in the current context.
Nevertheless, statins are known to inhibit Nuclear factor
kappa B (NFkB) activation and might help in blunting the
cytokine storm [44].
Similarly, to the case of diabetes, the literature review
on the link between medications prescribed for man-
aging hypertension and severity of Covid-19 finds no
conclusive evidence. In a review by Hessami et al. [28] in
9 studies that were included, with a total of 10.900
Covid-19 cases, the random-effects analysis showed a
combined OR for severity 0.76 (95% CI 0.39–1.49).
Moreover, in their study there was a high heterogeneity
indicating that there was no association between use of
ACEI/ARB and Covid-19 severity. Continuation of on-
going treatment, coupled with self-management and re-
mote interventions has also been suggested in the
context of other chronic illnesses such as asthma [50].
Conclusions and policy implications
There are a few conclusions that stem from this compre-
hensive literature review on the link between NCDs and
Covid-19. First, patients with certain chronic illnesses
such as diabetes, hypertension (and other cardiovascular
diseases), chronic respiratory illnesses, chronic kidney
and liver conditions are more likely to be affected by
Covid-19. This is further attested by the high prevalence
of some of these chronic illnesses (such as diabetes and
hypertension) among Covid-19 patients. More import-
antly, once they do get infected by the virus, patients
with chronic illnesses have a much higher likelihood to
either develop a more severe illness than an average pa-
tient; moreover they are more likely to die relative to pa-
tients who do not have chronic illnesses. Our literature
review presents evidence on this obtained both from
case- controlled studies as well as from other literature
reviews that we distilled. Third, while the research on
the reasons behind the high susceptibility of NCD pa-
tients to Covid-19 is still ongoing, researchers have
hypothesised two main channels: (i) increased ACE2
(angiotensin-converting enzyme 2) receptor expressions,
which facilitates the entry of the virus into the host
body; and (ii) hyperinflammatory response, referred to as
“cytokine storm”. Our literature review points out that
these transmission mechanisms are at play when it
comes to all Covid-19/NCD linkages. Finally, the litera-
ture review does not find any evidence that diabetes or
hypertension related medications exacerbate the overall
Covid-19 condition in chronic illness patients. Based on
this there are a few implications/policy recommenda-
tions that stem from this research. First, it is recom-
mended that patients continued with existing treatment
for chronic illnesses, especially as there is no evidence
that certain medications (e.g. for managing diabetes or
hypertension) are associated with worse Covid-19 clin-
ical outcomes. Second, there should be a greater em-
phasis on telemedicine and virtual visits. With physical
distances no longer a factor, virtualizing the care pro-
vided by diabetes educators, dieticians, and specialized
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mental health professionals could improve access further
than what was previously possible with in-person en-
counters [51]. Third, through the virtual visits there
should also be an improvement in patient education and
self-management [52]. Fourth, given the ongoing Covid-
19 vulnerabilities among people with NCDs, prioritizing
them for the vaccination process should also figure high
on the agenda on health authorities. Finally, all of the
steps above have to be done in resource-constrained set-
ting, with resources being diverted to Covid-19 needs.
Thus and going beyond just covering the immediate
needs to patients, health system strengthening, while
putting particular emphasis on primary healthcare, could
go long way in providing effective and safe management
of chronic illnesses [53].
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